On November 18, 2025 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), reported a business update and announced its financial results for the third quarter 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The third quarter was marked by solid and positive clinical and operational execution. Our clinical, manufacturing and regulatory teams are heavily focused on moving Ampligen down a pathway toward eventual FDA approval as part of a combination therapy for pancreatic cancer. We recently reported positive mid-year safety and efficacy data in the ongoing DURIPANC clinical trial combining Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi – or durvalumab – in the treatment of metastatic pancreatic cancer and, as an important inflection point, we will release a year-end update by the end of the current quarter. While we have more work ahead, the foundation we are building gives us confidence in our ability to deliver long-term value," commented AIM Chief Executive Officer Thomas K. Equels.
Additional Recent Highlights
Announced the presentation of data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), conducted by the University of Pittsburgh Medical Center at the 40th Annual Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting;
Granted European Patent No. 4,096,675, titled "Compositions for Treating LONG COVID," covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen for use in the treatment of Long COVID;
Secured patent in Japan through 2039 for novel cancer therapy combining Ampligen with checkpoint inhibitors;
Peer-reviewed article published in Journal for ImmunoTherapy of Cancer (JITC) providing evidence of a positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival;
Presented latest positive progress from Ampligen clinical programs in pancreatic cancer at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care hosted by and at Poland’s National Institute of Oncology in Warsaw, Poland.
For more information, please visit the Company’s website at aimimmuno.com.
Summary of Financial Highlights for Third Quarter 2025
As of September 30, 2025, AIM reported cash, cash equivalents and marketable investments of $2.4 million.
Research and development expenses for the three months ended September 30, 2025 were approximately $607,000, compared to $1.4 million for the same period in 2024.
General and administrative expenses were approximately $1.8 million for the three months ended September 30, 2025, compared to $3.1 million for the same period 2024.
The net loss from operations for the three months ended September 30, 2025 was approximately $(3.3 million), or $(1.57) per share, compared to $(3.7 million), or $(6.00) per share, for the three months ended September 30, 2024. This net loss includes non-recurring expenses. The Company expects a monthly burn rate of approximately ~ $550,000 while continuing operational efficiencies and a focused allocation of resources. This burn rate differs from the net loss above, as the net loss includes non-cash items and accounting adjustments, whereas burn rate isolates true operating cash outflows.
Please refer to the full September 30, 2025 Form 10-Q for complete details.
On November 17, 2025, AIM filed an extension with the SEC, giving the Company an additional five days to timely file its September 30, 2025 Form 10-Q. That 10-Q was subsequently filed yesterday.
(Press release, AIM ImmunoTech, NOV 18, 2025, View Source [SID1234660048])